- NewsCategory：
- All Company news Industry news
common105One result
-
1011
Viela Bio Enters Strategic CollaboΩ'ration with Mitsubishi Tanaσ"$≠be Pharma to Develop and Commercialize Ineb™$ilizumab for Autoimmu↓$δne Diseases in Japan an≥✘d Other Asia Regions
THURSDAY, OCTOBER 10, 201♥¶<↓9Viela Bio, Inc. and Mitsubishi Tana♥↓be Pharma Corporation (“M∑αTPC”) today announced a α♣collaboration focused on the devγ®φelopment and commercialization of ineb∏≠ ilizumab – Viela’s humanized anti-C ''ΩD19 monoclonal antibody – in nine Asia regionsσ for neuromyelitis optica spectrum disorder (NMO§↔ΩSD), as well as other →✔←potential future indications.“This pa☆×αrtnership adds to our ability to commerc±βialize inebilizumab globally, subject to regulatoπεry approval,” commented "≠Bing Yao, Ph.D., Viela’s Executive Cha€₽irman and Chief Executi♣γve Officer. “As a well-established pharmaceutica♦$φl company in Japan, Mitsubishi Tanabe has strong →←☆product development and commerciali↑£zation capabilities in AsΩ® ia, and we believe, is an ideal partner £≤for expanding inebilizumab’s potential←♦ reach to thousands of additio•× nal patients in need of viable treatments, with γ"€®NMOSD as an initial indication.”Under terms of↑•• the collaboration, Viela will receive anφ ®ε up-front licensing fee of $30 milli♥on as well as additional payments co©£©ntingent on certain develop$©₽≠ment and commercial mileston☆↑®es, plus payments based, i ><n part, on sales revenue.☆÷ MTPC will be responsible for leading deve δ→±lopment and commercializati¶§♣♥on of inebilizumab i&€©n Japan, Thailand, South Korea, Indonesia,₽₽☆→ Vietnam, Malaysia, Philippines, Singapore, and Tππβaiwan.“Our organization is ₩λ×delighted to partner with Viela to dev '€elop and commercialize their promising prod<↔uct candidate inebilizumab for autoimmune ¶γand inflammatory diseases,” said Masaβ☆yuki Mitsuka, MTPC President &≈"φ; Representative Direct σor. “Inebilizumab is an exciting produ₽↑δct candidate that, based₩¶ε on the results from the N-♣↕₹γMOmentum pivotal study, φis well-positioned to≠≥ provide meaningful benefit for patie ♠∞↑nts with NMOSD, and pot®♥₽≈entially additional diseaseγ♦s, subject to regulatory approval. We are₽÷÷ excited to work with Vi✔®€ela to advance inebilizumab in Japan and₹♠ε₽ other Asia regions, >π♠∏and look forward to a productive partnership ↔₩↓between our companies.”The U.S. Food and Drug Adm✘≠inistration (FDA) recΩ∞αently accepted for review Viela’s Biologics'± License Application (BLA) for inσ ♥ebilizumab for the trea¶ &tment of NMOSD. information&'♠>nbsp;source:pharma focus✘λ' AsiaThe original link:https:https:→ φ//www.pharmafocusasia.com/news/viela-b≥₩"io-enters-strategic-collaboration-withπ→-mitsubishi-tanabe-pharma-to-dε←∞evelop-and-commercialize-inebilizuma≈λ ₽b-for-autoimmune-diseas×π₩ es-in-japan-and-other-asia-regions2019 Asia-pa♦☆cific pharma IP Leader Summit: http://en.zenseeg←₩¥≥roup.com/p/510934/will be held in Beijing&§₩×∑nbsp; on November 14-15÷₹☆, and will attract more than 5¶&00 industry experts from domestic and forπβ↑eign pharmaceutical comp&✔βεanies, biotechnology companies, governments,₹Ω• associations, law firms, ♦δintellectual property agents and other ♣∞≤Ωcompanies to attend.Official r∞egistration and consultation channels:Contact：Ann☆ £λPhone: 021-65650305Email：Marketing@zense₹ δegroup.comhttp://en.zenseegroup.com/p/51δε ←0934/ -
1010
4D Pharma collabor4D Pharma' collaborates with MSD to develop l¶®₹ive biotherapeutic products for vaccinesates with¶λ♥ MSD to develop live biotherapeutic product≠₹s for vaccines
4D pharma plc, a leading pharmaceutλ&₹ical company in the deveπδlopment of live biotherapeutics, todayπ∞±β announces that the company has entered ¶Ω♠into a research collaboration agree©σδment and an option license to use with ★λ♦MSD (trading name of σ Merck & Co., Inc., in Kenilworth ,£ ↕ New Jersey , United States of£¥↔ America) to Discover and Develop Live "γBiotherapeutic Produc®&ts ("LBP") for vaccines.Under the term♥★≥s of the agreement, MicroRx®, the proprietary plaγ→tform of 4D, will be associatedε∑ with MSD's expertise in the developme€λ©$nt and commercialization of new ≈₹•vaccines, in order to disco•∏∏ver and develop LPBs as vaccines in maximum ≈✘"≈three undisclosed indications. β©4D has the right, subject to cer♣βtain conditions, to purch∏©<ase from MSD for $ 5 mill♠♣♥αion common shares of 4D during the f"πirst 12 months of the collaboration. In π↔addition to an initial c≥≤✘≈ash payment, for each i®"&ndication, 4D will be eligible to receive up to≈λ $ 347.5 million in exercise of options and $§₹regulatory and development milestone payments✔≤ ≤, as well as royalties the annu₽"al net sales of any licensed product resulting fr¥π★om the collaboration.Duncan Peyton , CEα←★∏O of 4D, said, "This collaborative res♣'<earch agreement brings togethe♥<λ↓r 4D's innovations in the mi♣↓crobiome field and M♥δ↕SD's track record in" the development of advanced vaccines. M≥&♣βSD and 4D worked closely to ♦☆×gether combining world-class scientific knowle>±±dge to develop a work♠" plan to advance understanding of t♦σ&→his field, with the goal☆Ω of generating a new class of vaccines in areas €÷¥where unmet needs are important. "Daria Hazuda , "₽Scientific Director of MSD's Explo♥γratory Science Center and Vice Presi≠βΩ dent of Research on MSD's Infectious Diseases and¥&•♠ Vaccines Discovery, said, "A key el♠®ement of our goal at t$™♥he Center for Exploratory Science is the¶∑©÷ assessment of emerging areas of emerging biology≥∑ that are likely to have a major b §eneficial impact on human health.↕✘™ By applying MicroRx® technology¶≤ of 4D, we hope to obtain useful information™♣€& on the role of the host microbiome in moε✘™$dulating the immune respλ&↔σonse and, ultimately, the protec♥♠γtion conferred by vaccines. "information sou<↑ rce:pharma focus AsiaThe original link:https:×&https://www.pharmafoc↕Ωusasia.com/news/4d-pharma∑δ-collaborates-with-msd-₹©σto-develop-live-biotherapeuti★✘÷∏c-products-for-vaccines2019 Asia-pacific ph∞≤φarma IP Leader Summit: http://e↕♥©→n.zenseegroup.com/p/510934/will be held in ↔';Beijing on Novem¶≈ber 14-15, and will attract more than ♠✔λ∞500 industry experts from domestic and €$foreign pharmaceutical companies, biotechn₹↔↓ology companies, governments, associεΩ÷ations, law firms, intell∏↓≠ectual property agents and other com₽≤ panies to attend.Official registration and c♣♣♠≥onsultation channels:Contact：AnnPhone: 0γφ£21-65650305Email：Marketing@zenseegroup.∞♠comhttp://en.zenseeg∑↕ ↕roup.com/p/510934/ -
1009
Goldfinch Bio Announces Lice λ nsing Agreement with Takeda for CB1 Mo"☆noclonal Antibody for the Treatment ofαα& Rare and Metabolic Kidney Diseases
Goldfinch Bio, a U.S.㥧-based, clinical stage biotechnology company fo &cused on discovering and developing precisioδ↓∑n medicines for the treatment of kidn↑φey diseases, today announced it entered ≠into a license agreement with Take ←da Pharmaceutical Company Limited™ $ (“Takeda”) for worldwide rights to a prec→↕♣♥linical, peripherally-restricted cannabinoid rece♥¶ ptor 1 (CB1) monoclonal antibody. Goldfinch Bio w✔÷≈¥ill assume all development and commer✔<δ≥cialization responsibilities for the ™treatment of rare and metabolic kidney diseases✔∏✘ worldwide. However, the agreement gr&☆ants Takeda the option, prior to the initiation "↔✔¥of pivotal studies, to reque≤st Goldfinch Bio negotiate with Takeda λ©©for sub-licensing of £♦Japanese rights to Takeda→γ. Financial terms of the agreement were not d♦®isclosed. Goldfinch Bio plans to file₩εΩ an investigational new drug (IND) a×≥®pplication for this ÷₩∞CB1 inhibitor, re-named GFB-024, in t™ λ≥he second half of 2020.“In recent yeλ<ars, our understanding of the role of CB1€σλ signaling in exacerbating pro∑☆gressive kidney disease≠ ∞↑s has grown substantially. In this ¥←context, a monoclonal antibody direδ"§"cted toward the CB1 receptor is potentially well€>π -suited to elicit the beneficial pharmacology assπ↓• ociated with the peripheral €inhibition of the CB1 receptor,” said Anthon×αy Johnson, M.D., President and Chief Executive§<Ω Officer of Goldfinch Bio♠§ . “Goldfinch Bio will depφ∏Ω≥loy its biology platfor✘↓×✘m and Kidney Genome AtlasTM to de♠§velop this therapeutic agent♣£ in subsets of patients with kidney diδ''seases most likely to pre≈€ferentially respond to CB1 inhibition. WithΩ≈ GFB-887, our TRPC5 inhibitor for FSGS, in Phase≥£ 1 clinical development, this peripheral C≥B1 inhibitor will be the second clinic-ready₽λα program in Goldfinch Bio’s pipeline. We β☆look forward to collaborating with Takeda on this↑δ&ε program.”“Goldfinch Bio is ideally≥→∏© suited to advance developmen₩≤$t of this program,” said Dan Cur≤ε↔©ran, M.D., SVP and He®↓ad, Rare Diseases Therapeutic Area™← Unit, Takeda. “The application of its precisi✔βon medicine approach, from ca≥←ndidate target validation ε↓♣βthrough to identification of ₩ ₩♣potential treatment-relevant subgroups, is uniqu≤$↕e in the development of chronic metab✘®olic kidney disease treatme ≠nts.”Preclinical data support the inhibition of CαB1 signaling as a novel treatment of Dia"✔betic Nephropathy (DN) a♦★nd obesity-related glomerulopathi★πes (ORG), given the potential metabolic bene✘•↓fits and direct effects on the kid∞>δney to prevent fibrosis≈♥∏ and preserve kidney function. DN de♦≈velops in 30 to 40 pγ♦ercent of patients who have diλ©abetes and is a leading cause of mo ÷ rbidity, mortality and£✘ end-stage kidney disease in $γthe United States and worldwide. ORG is a r→×are kidney disorder characterized by significant↔€ proteinuria and progressive ren®₽al dysfunction. Although both DN and ORG ar§∑©e increasing in prevalence in parallel with th&§σe obesity epidemic, well-est∞ →↕ablished disease modifying↔δ ♥ therapies are lacking.₹φ™ Goldfinch Bio plans to initiate a phase 1"♠ study for GFB-024 in 2H 2020.$∏ ←information source:pharma focus AsiaTh±¥e original link:https://www.pharmafocusasiaπ•.com/news/goldfinch-bi×ββ¶o-announces-licensing-agreement-↓≥βwith-takeda-for-cb1-m•δ↑onoclonal-antibody-for-the-treatment-of-rare-a✔☆nd-metabolic-kidney-d→₹iseases2019 Asia-pacif↔ ₽ic pharma IP Leader Summit: http:/₹$™/en.zenseegroup.com/p/404716/ will ₩★be held in Beijing ¶λ✔•on November 14-15, and will attract more♠↕α than 500 industry experts from domestic and f♠ <÷oreign pharmaceutical companies, biotechnolo→βgy companies, governments, associations, l >aw firms, intellectual property agents and₹✔™' other companies to attend.Official r•¥&egistration and consultation channels:Contact：δ AnnPhone: 021-65650305Email：Marketing@zenseeg≥α←<roup.comhttp://en.zenseegroup.c↔om/p/510934/ -
1008
Prometheus Biosciences, Iα☆γ®nc., Enters Into Multi-Target Strγπ→ategic Collaboration wiε∏ th Takeda to Develop Tar'™geted Therapies for Inflammato<↔≥×ry Bowel Disease
Prometheus Biosciences, Inc., a∏÷ biopharmaceutical companyβ♥∏$ committed to the discovery, development, and co↑δπ®mmercialization of a broad portfolio of novel p∑ λrecision therapeutics and companion diagnostic↑λs for patients living with unmet needs$γ< in gastroenterology and autoim£'mune diseases, announced €₹that it has entered into a gλ♦♠ lobal, multi-target strategic£∑ε collaboration with Tak♥ ≠∏eda Pharmaceutical Company Limiφ± ted (Takeda) to discover, deΩ∑₽velop, and commercialize nov←♣←≥el therapies for inflammator≠λ♠y bowel disease (IBD). The collaboration combin£ es the proprietary bioinformatics discovery p→₽latform and companion≈π↕≈ diagnostic tools developed by Prometheus Biosci₹®ences with Takeda's expe↑☆¶rtise in gastroenterology and drug develπ≈ ↔opment, in order to discover and advance π×≥≤up to three targeted I±™BD therapeutics and compan§£₹•ion diagnostics. Prometheus Bios©∏ciences will be responsible£↑ for the identification and ₹ validation of three unique drug targγ®'γets for IBD, along with the d↕£§♥evelopment and commercialization of companion ♠♦diagnostics to complement the targeted drugs. T≠∑εakeda will be responsible for all d≤₽rug discovery, clinical development, a∏↑¶nd commercialization act§✔ivities for the resulting targete₹®★d therapeutics."We are impresse≠≠d with Takeda's commitment to de™βveloping a portfolio of th₹βerapies to address all IBD patients, eσ±"γspecially those with unmet÷€γ needs," said Mark McKenna, chief ex✘φecutive officer, Prometheus Biosciences. "W₩←πe believe that a targeted, precision medic≤ine approach is need£✘ ed to deliver new, effective th±≥erapeutic options in inflammatory×₹ bowel disease. Through our partnership, we₩× are excited to combin ♣e the Prometheus bioinformβatics platform and advanced machine leaλ☆✔αrning techniques with Takeda'>&s expertise in drug development to deliver a ∏§£new generation of IB↔×D therapies."Under the terms of the →± agreement, Prometheus Bioscien< ces will receive an un≈™disclosed initial upfront payment from Takeda and∞∏ is eligible to receive up to $420↔γ&M in development, regulatory,ε€♦ and commercial milestone payments, in total,♠ φ∑ across all three programs. In addition, Pr•± ¥ometheus Biosciences is eligible to↕©" receive royalty payments on global commercial saβ₽₽les from each program.information&nbs≥←♦βp;source:pharma focus AsiaThe origi✔φnal link:https:https://±©www.pharmafocusasia.com/news/prometheus-biosc♠€iences-inc-enters-into-mul®₩™♥ti-target-strategic-co★llaboration-with-takeda-to-dev←∑elop-targeted-therapies-for-infla§↕ mmatory-bowel-disease2019 Asia-pacif♠ic pharma IP Leader Summit: http://e ®™n.zenseegroup.com/p/510934/ will ε∑₩ be held in Beijing&÷₩₩nbsp; on November 14-15, and↕←♥≈ will attract more than 500 industry Ω♦δexperts from domestic a♥₹nd foreign pharmaceutical c>∞>✔ompanies, biotechnology companies, governmentsש>∏, associations, law firms, intellectual £<property agents and other companies to attend→↓₩.Official registration and consultation "λδchannels:Contact：AnnPhonα>π e: 021-65650305Email：Mar₹☆keting@zenseegroup.comhttp://eδ♠ n.zenseegroup.com/p/510934/ -
0929
Catabasis Pharmaceuticals and the Jain Foundat≠♥ion Announce a Preclinical Research Collaborat✔¥βion to Study Edasalonexent in Dysferlinopathy
Catabasis Pharmaceuticals, I≈nc., a clinical-stage bσ→₩iopharmaceutical com≤'™↓pany, and the Jain Foundation, a non-profit founδ✔αdation whose mission is >§to cure muscular dystrophies caused by dysferliε•♠n protein deficiency, announc×÷ed a preclinical research co±©₽llaboration to study ed→®asalonexent (CAT-1004) in Dysferlinopathy. Dysf£ erlinopathy (Limb-girdle muscu♣♥lar dystrophy type 2B /<α™ Miyoshi myopathy) is¥↓φ a serious rare disease that causes pro"σ€"gressive muscle weakness for which there are¥≤ currently no approved treatγ∏≥ment options. Edasalo&∞nexent is in Phase 3 develoΩ♦£pment for the treatmen±∞σ t of Duchenne muscularδ≠♣ dystrophy (DMD) and λ$has the potential to benefit pat♥×ients with other diseases, such as Dysfeβו'rlinopathy.In Dysferlinopathy, muscles lack dysfλ₽±erlin and as a result NF-kB is chronically ↕δ¥→activated. Edasalonexent, a®±∞n oral small molecule designed to inh©∏♦ibit NF-kB, has the potential to slow disease pro φgression in dysferlin-defic∞α$ient populations. Under this collaboration, Catabδγasis and the Jain Foundation are conducting a pr✔↕eclinical study to evaluate th×α¶e potential of edasalonexent as a therapeuti&™•c intervention for Dysferlinop'♠®athy by measuring disease progressio¶★§n in dysferlin-deficient mice treated with edasal'→Ωonexent. The study will utilize magnetα∏ ∏ic resonance imaging (MRI) and m↑↑agnetic resonance spectroscopy (MRS) to mea↔×<sure muscle volume, fat accumulation§&↓, and other changes in the dysferlin-deficie£→₽εnt mice. Initial results are expected in™£☆£ the first half of 202 '0.“We look forward to working☆↔♠ with Catabasis to advance $€♦research for Dysferlinopathy,” said Laura Rufib✘←±ach, Ph.D., and Doug A"♠±'lbrecht, Ph.D., Co-Presi✘→ dents of the Jain Foundation₩÷£. “Patients with Dysferlinopathy (LGMD2B / Miyos< hi myopathy) experience a pro∞ "gressive and debilitating declin♥★≥♠e in muscle function which significant™ ly impacts their lives. As ₹×there are currently no treatment options, w'•e are excited to explore the potentia≥≥×♠l of edasalonexent to benefit 'γ those living with this disease.”“Th₹λγ→e chronic activation of NF-kB is a key driver i↓€'®n many neuromuscular disorders&$, including Duchenne muscular dystrophy. Evidenceε∞₹ of NF-kB activation in Dysferlino×¥pathy suggests a similar disease mechanism and≥♣ opportunity for interven∞∞✔tion. In the MoveDMD trial and open-label ×↓extension, treatment with edasalonexent slowe→₽φ≤d disease progression compared to the off-tr₽×eatment control period. Through this cε$ ollaboration, we look forward to learning mor↑♠e about the potential of edasalo₹δ≠nexent in Dysferlinopathy, where, similar to∞÷₹ Duchenne, there is also a signif≥♦icant unmet need,” said Andrew Nichols, Ph.D., ε" ♠Chief Scientific Officer at Catabas☆'¥πis Pharmaceuticals.information source£&:pharma focus AsiaThe original link:https$<λ∞:https://www.pharmafocusasia.com/n☆<♦ews/catabasis-pharmaceuticals-and-the-jai♦∞n-foundation-announce-a-preclinical-research₩≈®♥-collaboration-to-study-edasalon★§£$exent-in-dysferlinopathy2019 Asi>•×a-pacific pharma IP Leader Summit: httpε≤ ://en.zenseegroup.com/p/404716/✘§ will be held in&nbs ♥✘'p;Beijing on November 14-15♦φ✔★, and will attract more than 500 industry $™↑experts from domestic and÷ foreign pharmaceutical companies, biotechnology ®£×companies, governments, associations, law f∑<irms, intellectual property σ agents and other comp•≠ anies to attend.Official registration >÷$∞and consultation channels:Contact：AnnPhone: 021×₹-65650305Email：Marketing@zenseegroup>±.comhttp://en.zenseegroup.com/p/510934/
Contact Us
Zensee_Daystar online
© 2011-2016